FDAnews

ASTELLAS PAYS $221 MILLION FOR RIGHTS TO THERAVANCE ANTIBIOTIC

Astellas Pharma Inc., Japan's second -- largest drugmaker, bought the right to test, make and sell an antibiotic called telavancin from Theravance Inc., a U.S. drugmaker. Tokyo -- based Astellas will pay $221 million to Theravance as an initial payment for the licensing agreement, the company said in a statement filed to the Tokyo Stock Exchange.

Bloomberg

(http://www.bloomberg.com/apps/news?pid=10000101&sid=asrYvupRNAPY&refer=japan)